[go: up one dir, main page]

NO962933L - Östradiol-penetrasjonsforsterker for transdermal administrering - Google Patents

Östradiol-penetrasjonsforsterker for transdermal administrering

Info

Publication number
NO962933L
NO962933L NO962933A NO962933A NO962933L NO 962933 L NO962933 L NO 962933L NO 962933 A NO962933 A NO 962933A NO 962933 A NO962933 A NO 962933A NO 962933 L NO962933 L NO 962933L
Authority
NO
Norway
Prior art keywords
ostradiol
transdermal administration
penetration enhancer
containing active
substances
Prior art date
Application number
NO962933A
Other languages
English (en)
Other versions
NO962933D0 (no
Inventor
Reinhold Meconi
Frank Seibertz
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of NO962933D0 publication Critical patent/NO962933D0/no
Publication of NO962933L publication Critical patent/NO962933L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Et plaster som inneholder virksom substans, for regulert avgivelse av øst- radiol eller dens farmasøytisk tilfreds- stillende derivater, alene eller i kom- binasjon med gestagener, av et bakre lag, et reservoar som er forbundet med dette og som inneholder virksomme sub- stanser, og som er fremstilt under an- vendelse av klebemidler og minst ett gjennomtrengningsforsterkende middel, samt et gjen-avløsbart beskyttelseslag, kjennetegnet ved at det gjennomtreng- ningsforsterkende middel -er valgt blant substanser på basis av karboksylsyrer.
NO962933A 1994-01-13 1996-07-12 Östradiol-penetrasjonsforsterker for transdermal administrering NO962933L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4400770A DE4400770C1 (de) 1994-01-13 1994-01-13 Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
PCT/EP1995/000032 WO1995019162A1 (de) 1994-01-13 1995-01-05 Estradiol-penetrationsverstärker zur transdermalen verabreichung

Publications (2)

Publication Number Publication Date
NO962933D0 NO962933D0 (no) 1996-07-12
NO962933L true NO962933L (no) 1996-09-12

Family

ID=6507821

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962933A NO962933L (no) 1994-01-13 1996-07-12 Östradiol-penetrasjonsforsterker for transdermal administrering

Country Status (22)

Country Link
US (1) US6090404A (no)
EP (1) EP0739199B1 (no)
JP (1) JP3980633B2 (no)
KR (1) KR100374087B1 (no)
AT (1) ATE215363T1 (no)
AU (1) AU707963B2 (no)
CZ (1) CZ287330B6 (no)
DE (2) DE4400770C1 (no)
DK (1) DK0739199T3 (no)
ES (1) ES2174922T3 (no)
FI (1) FI118719B (no)
HU (1) HU222499B1 (no)
IL (1) IL112145A (no)
MY (1) MY113680A (no)
NO (1) NO962933L (no)
NZ (1) NZ278593A (no)
PL (1) PL184875B1 (no)
PT (1) PT739199E (no)
SI (1) SI0739199T1 (no)
SK (1) SK280530B6 (no)
WO (1) WO1995019162A1 (no)
ZA (1) ZA95226B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2000062753A1 (de) * 1999-04-16 2000-10-26 Jenapharm Gmbh & Co. Kg Pharmazeutische oder kosmetische zusammensetzungen zur lokalen, intradermalen applikation von hormonen
US6974588B1 (en) * 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
GB0103046D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
BR0205990A (pt) * 2001-08-29 2004-01-13 Ricardo Azevedo Ponte Carvalho Um sistema implantável de liberação unidirecional de agentes terapêuticos para tecidos
WO2004064757A2 (en) * 2003-01-23 2004-08-05 Shire Laboratories, Inc. Absorption enhancing agents
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
US20070042026A1 (en) * 2005-03-17 2007-02-22 Wille John J Prophylactic and therapeutic treatment of topical and transdermal drug-induced skin reactions
US8372040B2 (en) 2005-05-24 2013-02-12 Chrono Therapeutics, Inc. Portable drug delivery device including a detachable and replaceable administration or dosing element
JP5162862B2 (ja) * 2005-09-16 2013-03-13 株式会社リコー 感熱性粘着剤及び感熱性粘着材料
US9555167B2 (en) * 2006-12-11 2017-01-31 3M Innovative Properties Company Biocompatible antimicrobial compositions
US20080200890A1 (en) * 2006-12-11 2008-08-21 3M Innovative Properties Company Antimicrobial disposable absorbent articles
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3471692B1 (en) * 2016-06-15 2019-10-30 Unilever N.V. Method and cosmetic composition for enhanced transdermal delivery of alkyl substituted resorcinol
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
MA54245A (fr) 2018-11-16 2022-02-23 Morningside Venture Investments Ltd Système d'administration transdermique de médicaments à régulation thermique
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115010949B (zh) * 2022-07-12 2024-02-13 华熙生物科技股份有限公司 促渗物、护肤品组合物以及化妆品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637224A (en) * 1969-02-27 1972-01-25 Fedders Corp Annular sealing ring
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
AU553343B2 (en) * 1981-08-10 1986-07-10 Advance Electrode Kabushikikaisya Absorbent adhesive bandage with medicament release
US4687481A (en) * 1984-10-01 1987-08-18 Biotek, Inc. Transdermal drug delivery system
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
ATE95430T1 (de) * 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
US4732892A (en) * 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
CH674618A5 (no) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE3743946A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
CA2000401C (en) * 1988-10-11 1996-05-28 Masato Azuma Percutaneous pharmaceutical preparation
CA2004203A1 (en) * 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
DE3843239C1 (no) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
AR246186A1 (es) * 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
US5252588A (en) * 1990-04-27 1993-10-12 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation
EP0483370B1 (en) * 1990-05-17 1995-03-29 Hisamitsu Pharmaceutical Co., Inc. Percutaneous preparation containing estradiol
US5122382A (en) * 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5518734A (en) * 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
DE4223360C1 (no) * 1992-07-16 1993-04-08 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
JPH06100439A (ja) * 1992-09-18 1994-04-12 Sekisui Chem Co Ltd 経皮吸収貼付剤

Also Published As

Publication number Publication date
CZ287330B6 (en) 2000-10-11
EP0739199A1 (de) 1996-10-30
US6090404A (en) 2000-07-18
NO962933D0 (no) 1996-07-12
HUT74455A (en) 1996-12-30
FI962702L (fi) 1996-08-27
EP0739199B1 (de) 2002-04-03
NZ278593A (en) 1997-12-19
DE4400770C1 (de) 1995-02-02
SK280530B6 (sk) 2000-03-13
PL315527A1 (en) 1996-11-12
KR970700021A (ko) 1997-01-08
DE59510142D1 (de) 2002-05-08
FI118719B (fi) 2008-02-29
CZ205396A3 (en) 1996-10-16
KR100374087B1 (ko) 2003-04-23
AU1455295A (en) 1995-08-01
MY113680A (en) 2002-04-30
PL184875B1 (pl) 2003-01-31
IL112145A0 (en) 1995-03-15
JP3980633B2 (ja) 2007-09-26
SI0739199T1 (en) 2002-10-31
ES2174922T3 (es) 2002-11-16
PT739199E (pt) 2002-09-30
ATE215363T1 (de) 2002-04-15
FI962702A0 (fi) 1996-06-28
DK0739199T3 (da) 2002-07-29
JPH09511229A (ja) 1997-11-11
IL112145A (en) 2000-10-31
HU222499B1 (hu) 2003-07-28
AU707963B2 (en) 1999-07-22
SK91596A3 (en) 1997-03-05
WO1995019162A1 (de) 1995-07-20
HU9601872D0 (en) 1996-09-30
ZA95226B (en) 1996-02-07

Similar Documents

Publication Publication Date Title
NO962933L (no) Östradiol-penetrasjonsforsterker for transdermal administrering
AU679032B2 (en) Transdermal therapeutic system with galanthamine as active ingredient
PT93191A (pt) Sistema terapeutico para a administracao retardada e controlada transdermica ou transmucosica de substancias activas
DK0889723T3 (da) Transdermalt terapeutisk system med ringe tykkelse af administreringsareal og stor fleksibilitet samt fremgangsmåde til fremstilling heraf
DK0665745T3 (da) Plaster til transdermal administrering af flygtige, farmaceutisk aktive, kemisk basiske indholdsstoffer samt fremgangsmåde
NO306378B1 (no) Transdermalt terapeutisk system inneholdende det aktive stoffet 17-<beta>-östradiol, samt fremgangsmaate for fremstilling av dette
WO2001026637A3 (de) Transdermales therapeutisches system zur abgabe von acetylsalicylsäure und/oder salicylsäure
CA2010225A1 (en) Therapeutic System for the Retarded and Controlled Transdermal or Transmucous Administration of Active Substances (1)
KR100549846B1 (ko) 활성물질 스코폴라민 염기를 함유하는 경피 치료 시스템
EE03135B1 (et) Transdermaalne terapeutiline süsteem füsostigmiini manustamiseks ja meetod selle valmistamiseks
CA2144441A1 (en) Dexpanthenol-containing plaster for the transdermal application of steroid hormones
CA2181072A1 (en) Estradiol penetration enhancers

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application